See more : NORMA Group SE (NOEJF) Income Statement Analysis – Financial Results
Complete financial analysis of IMARA Inc. (IMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMARA Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nuvo Pharmaceuticals Inc. (MRV.TO) Income Statement Analysis – Financial Results
- Best Agrolife Limited (BESTAGRO.NS) Income Statement Analysis – Financial Results
- RSWM Limited (RSWM.BO) Income Statement Analysis – Financial Results
- World Known MFG (Cayman) Limited (4581.TW) Income Statement Analysis – Financial Results
- Ashington Innovation PLC (ASHI.L) Income Statement Analysis – Financial Results
IMARA Inc. (IMRA)
About IMARA Inc.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.94M | 38.44M | 32.15M | 19.01M | 8.24M |
| General & Administrative | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Other Expenses | -97.00K | -175.00K | -145.00K | 75.00K | 0.00 |
| Operating Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Cost & Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Interest Income | 943.00K | 233.00K | 483.00K | 578.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -69.39M | 99.00K | 97.00K | 33.00K | -660.00K |
| EBITDA | -68.66M | -51.34M | -41.60M | -24.08M | -11.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 730.00K | -51.44M | -41.70M | -24.12M | -10.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 846.00K | 58.00K | 338.00K | 653.00K | -660.00K |
| Income Before Tax | 1.58M | -51.38M | -41.36M | -23.46M | -11.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 88.00K | -233.00K | -483.00K | -578.00K | 0.00 |
| Net Income | 1.58M | -51.15M | -40.88M | -22.89M | -11.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| EPS Diluted | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| Weighted Avg Shares Out | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
| Weighted Avg Shares Out (Dil) | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
5 Top Penny Stocks With Unusual Options Activity Today
Penny stocks to watch with unusual options activity today. The post 5 Top Penny Stocks With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Makes IMARA Inc. (IMRA) a New Buy Stock
IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read Why Imara Shares Are Falling Today
Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. Data from the sickle cell disease study interim analysis demonstrated that.
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will...
Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February
Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D.,...
Imara To Start Testing Tovinontrine In Heart Failure Patients
The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to initiate a Phase 2 trial in Q2 of 2022 to evaluate tovinontrine in patients 45...
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that...
Source: https://incomestatements.info
Category: Stock Reports